Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: A biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Fuernau, Georg ^a   Pöss, Janine ^b,c   Denks, Daniel ^a   Desch, Steffen ^a,b   Heine, Gunnar H ^c   Eitel, Ingo ^a,b   Seiler, Sarah ^c   de Waha, Suzanne ^a,d   Ewen, Sebastian ^c   Link, Andreas ^c   Schuler, Gerhard ^a   Adams, Volker ^a   Böhm, Michael ^c   Thiele, Holger ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Segeberger Kliniken GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BODY MASS; CARDIOGENIC SHOCK; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAAORTIC BALLOON PUMP; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; COMPLICATION; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SHOCK, CARDIOGENIC; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CREATININE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INTRA-AORTIC BALLOON PUMPING; KAPLAN-MEIER ESTIMATE; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; SHOCK, CARDIOGENIC; TREATMENT OUTCOME;

EID: 84924253250     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0713-8     Document Type: Article

References (33)

1. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999, 340:1162-1168.
2. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J: Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009, 119:1211-1219.
3. Kouraki K, Schneider S, Uebis R, Tebbe U, Klein HH, Janssens U, Zahn R, Senges J, Zeymer U: Characteristics and clinical outcome of 458 patients with acute myocardial infarction requiring mechanical ventilation. Results of the BEAT registry of the ALKK-study group. Clin Res Cardiol 2011, 100:235-239.
4. Hochman JS: Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003, 107:2998-3002.
5. Ellam TJ, Chico TJ: Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012, 220:310-318.
6. Larsson TE: The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010, 25:1376-1381.
7. Heine GH, Seiler S, Fliser D: FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant 2012, 27:3072-3081.
8. de Borst MH, Vervloet MG, ter Wee PM, Navis G: Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011, 22:1603-1609.
9. Poss J, Mahfoud F, Seiler S, Heine GH, Fliser D, Bohm M, Link A: FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2013, 2:211-218.
10. Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, Fliser D, Heine GH: Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol 2014, 9:1049-1058.
11. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014, 25:349-360.
12. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
13. Heine GH, Nangaku M, Fliser D: Calcium and phosphate impact cardiovascular risk. Eur Heart J 2013, 34:1112-1121.
14. Lutsey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, Loehr LR, Eckfeldt JH, Coresh J: Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014, 3:e000936.
15. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'Donnell TF, Vora AN, Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS: Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014, 63:2421-2428.
16. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
17. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
18. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009, 207:546-551.
19. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Bohm M, Fliser D, Heine GH: The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011, 32:2688-2696.
20. Agarwal I, Ide N, Ix JH, Kestenbaum B, Lanske B, Schiller NB, Whooley MA, Mukamal KJ: Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014, 3:e000584.
21. Thiele H, Schuler G, Neumann FJ, Hausleiter J, Olbrich HG, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Bohm M, Kurowski V, Lauer B, Minden HH, Figulla HR, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SK, Mollmann H, Schneider S, Ebelt H, Werdan K, Zeymer U: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 2012, 163:938-945.
22. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K: Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012, 367:1287-1296.
23. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G: Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013, 382:1638-1645.
24. Seiler S, Wen M, Roth HJ, Fehrenz M, Flugge F, Herath E, Weihrauch A, Fliser D, Heine GH: Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013, 83:121-128.
25. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012, 122:2543-2553.
26. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012, 60:200-207.
27. Razzaque MS: The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009, 5:611-619.
28. Kawai M, Kinoshita S, Shimba S, Ozono K, Michigami T: Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J Biol Chem 2014, 289:1457-1466.
29. Cunningham SG, Knowlton GG, Sanders JB: Plasma renin activity levels in two patients with impending cardiogenic shock. N Engl J Med 1982, 306:993-994.
30. Dominguez JR, Shlipak MG, Whooley MA, Ix JH: Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol 2013, 24:647-654.
31. Amrein K, Zajic P, Schnedl C, Waltensdorfer A, Fruhwald S, Holl A, Urbanic Purkart T, Wunsch G, Valentin T, Grisold A, Stojakovic T, Amrein S, Pieber TR, Dobnig H: Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. Crit Care 2014, 18:R47.
32. Venkatram S, Chilimuri S, Adrish M, Salako A, Patel M, Diaz-Fuentes G: Vitamin D deficiency is associated with mortality in the medical intensive care unit. Crit Care 2011, 15:R292.
33. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG: FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014, 6:744-759.